Abelmoschus manihot (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
66 | IgA nephropathy | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02231125 (ClinicalTrials.gov) | September 2014 | 30/8/2014 | Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy | Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial | IgA Nephropathy | Drug: Losartan;Drug: Abelmoschus manihot | Chen Xiangmei | Jiangsu Suzhong Pharmaceutical Group Co., Ltd. | Recruiting | 18 Years | 65 Years | Both | 1600 | Phase 4 | China |